Ascendis Pharma A/S (ASND)
Market price: $249.55
2 valuation methods
- EV / Gross Profit: $55.58 to $115.93 (midpoint $79.64)
- EV / Revenue: $44.44 to $141.09 (midpoint $87.87)
How each method works
EV / Gross Profit: $55.58 to $115.93 (midpoint $79.64)
Values the business at a peer multiple of gross profit — useful where reported operating costs vary a lot across peers but gross economics are comparable.
- How it’s calculated
- We take last-twelve-month gross profit (revenue minus the direct cost of the goods or services sold), multiply it by the peer range of EV/Gross-Profit multiples, subtract net debt and any minority interests or preferred stock ranking ahead of common shareholders, and divide by shares outstanding.
- Why it fits this industry
- Gross profit sits between revenue and operating earnings: it credits the margin a company's products earn while ignoring overhead and investment choices that legitimately differ across peers.
- Reading this bar
- The bar is the per-share value range this method implies: a conservative low, a central estimate, and an optimistic high. If the current price sits below the bar, the market is pricing the shares below what this method's inputs suggest; if it sits above, the market is pricing them higher. No single bar is a verdict — methods disagree for good reasons, so read the whole field together.
EV / Gross Profit = (5.46/7.57/10.75)× gross_profit 706,484,667.13 ≈ 3,855,865,693.84/5,347,261,516.65/7,596,661,387.46 (enterprise_value); enterprise_value -> per share: equity (3,444,465,293.84/4,935,861,116.65/7,185,260,987.46) / 61,977,408 shares [EV bridge: minus net debt 411,400,400.00]
EV / Revenue: $44.44 to $141.09 (midpoint $87.87)
Values the whole business at a peer multiple of sales — used when earnings are thin, volatile, or not yet meaningful, so revenue is the most reliable yardstick.
- How it’s calculated
- We multiply the company's last-twelve-month revenue by the range of EV/Revenue multiples its peer group trades at, subtract net debt and any minority interests or preferred stock ranking ahead of common shareholders, and divide by shares outstanding for a per-share range.
- Why it fits this industry
- When profits are thin, volatile, or still to come, revenue is the most dependable figure a company reports — this method values the business on the scale of what it actually sells.
- Reading this bar
- The bar is the per-share value range this method implies: a conservative low, a central estimate, and an optimistic high. If the current price sits below the bar, the market is pricing the shares below what this method's inputs suggest; if it sits above, the market is pricing them higher. No single bar is a verdict — methods disagree for good reasons, so read the whole field together. A pound of revenue is worth more at a high margin than a low one, so the peer group here is narrowed to companies earning a similar margin wherever enough of them exist. Where too few do, the bar falls back to the wider group and is the bluntest of the multiples — weigh it alongside the earnings-based bars.
EV / Revenue = (3.89/7.20/11.25)× revenue 813,737,016.60 ≈ 3,165,541,224.71/5,857,434,483.36/9,156,071,714.44 (enterprise_value); enterprise_value -> per share: equity (2,754,140,824.71/5,446,034,083.36/8,744,671,314.44) / 61,977,408 shares [EV bridge: minus net debt 411,400,400.00]
5 methods not shown
- EV / EBITDA: EBITDA is non-positive — an EBITDA multiple yields no meaningful enterprise value (loss-making at the EBITDA line)
- P / E: diluted EPS is non-positive — P/E is not meaningful for a loss-making period
- P / B: book value per share is non-positive (negative common equity) — P/B is not meaningful
- DCF (FCFF): DCF input(s) unavailable (capex) — cannot build FCFF
- P / E — adjusted: adjusted_eps unavailable — cannot form P / E — adjusted
Limited data — fewer than three valuation methods could be formed for this company; showing every method we can stand behind.